Ginkgo bioworks provides preliminary unaudited 2022 revenue highlights and business review

Expects to meet 2022 guidance ranges for total revenue and new cell programs year end cash balance of approximately $1.3 billion provides ample liquidity and puts ginkgo in a position of strength to continue to build its leadership position despite a challenging macroenvironment strong growth among biopharma customers as ginkgo has scaled its mammalian cell engineering capabilities, including recently opening bioworks7, which is fully dedicated to mammalian cell engineering workflows management to highlight updates today at the 41st annual j.p. morgan healthcare conference at 11:15 a.m.
DNA Ratings Summary
DNA Quant Ranking